{"references": ["Vol 327:N\u00ba 16; p\u00e1gs. 1552-54. 2022. Brett AS. Should Patients Take Aspirin for Primary Cardiovascular Prevention? Updated Recommendations From the US Preventive Services Task Force . JAMA. DOI: http://doi.org/10.1001/jama.2022.2460", "Vol 164:N\u00ba 12; p\u00e1gs. 836-45. 2016. Bibbins-Domingo K; US PreventiveServicesTask Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. DOI: https://doi.org/10.7326/M16-0577", "Vol. 392 :N\u00ba 10152; p\u00e1gs. 1036-46. 2018. Gaziano JM, Brotons C, Coppolecchia R, et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. DOI: https://doi.org/10.1016/S0140-6736(18)31924-X", "Vol. 379:N\u00ba 16; p\u00e1gs. 1509-18. 2018. McNeil JJ,Wolfe R,Woods RL, et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. The New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa1805819", "Vol. 379:N\u00ba 16; p\u00e1gs. 1529-39. 2018. Bowman L, Mafham M,Wallendszus K, et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. The New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa1804988", "Vol. 42:N\u00ba 2021; p\u00e1gs. 3227-37. 2021. F.L.J. Visseren, F. Mach, Y.M. Smulders, et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. DOI: http://dx.doi.org/10.1093/eurheartj/ehab484"]}

El uso de aspirina en la prevención secundaria de la patología cardiovascular ofrece un claro beneficio neto, pero su administración como prevención primaria es controvertida. Se comenta la actualización en las recomendaciones sobre el uso de aspirina en prevención primaria de enfermedad cardiovascular (ECV) y de cáncer de colorrectal (CCR) realizada por el grupo de trabajo de servicios preventivos de EEUU (USPSTF).